Search for: "OSI, Inc."
Results 61 - 68
of 68
Sort by Relevance
|
Sort by Date
21 Oct 2008, 5:39 pm
Thirty two counts charged six Treasury employees and two employees of OSI Collection Services, Inc., a vendor selected by the State, after competitive bidding, to collect tax deficiencies and delinquencies, with official misconduct. [read post]
29 Aug 2008, 1:25 pm
Here is IP Think Tank’s weekly selection of top intellectual property news breaking in the blogosphere and internet. [read post]
6 Aug 2008, 4:31 pm
We have recently seen this trend among large companies: Adobe Systems, Inc. released Flex and Nokia releasing the Symbian operating system under an open source license. [read post]
18 Mar 2008, 9:43 am
OSI Pharmaceuticals Inc. announced in a press release that the decision of the European Patent Office (EPO) to revoke one of the company's dipeptidyl peptidase IV (DP-IV) patents, EP0896538, claiming the use of DP-IV inhibitors to treat type II diabetes and related indications, has been upheld in appeal proceedings brought by the company.Click here for OSI press release. [read post]
29 Feb 2008, 8:00 am
– Teva’s opposition proceedings regarding IL 130424 to Pfizer: (IP Factor), Thailand: Thai chief drug price negotiator removed from post: (GenericsWeb), Thailand: Compulsory licences cannot be revoked: (Generic Pharmaceuticals & IP), (more from Generic Pharmaceuticals & IP), UK: Court of Appeal for England and Wales hands down decision in Boehringer Ingelheim KG and Boehringer Ingelheim Pharma KG v Swingward Limited relating to repackaging and de-branding of… [read post]
19 Dec 2007, 7:38 am
Network Appliances, Inc. [read post]
23 Jun 2007, 4:00 pm
Tiemann argues that the term should only be used to refer to licenses and software that adhere to the OSI's definition of open source. [read post]
29 Jun 2006, 5:04 pm
" Experimental Cancer Drug Tarceva Reuters, October 9, 2002 NEW YORK (Reuters Health) - OSI Pharmaceuticals Inc. is more confident than ever of the potential of its experimental cancer drug Tarceva (erlotinib HCl), even after the failure of a similar drug in a major clinical study this summer, OSI Chairman and CEO Dr. [read post]
